NewcelX Ltd. has made a significant move by entering into a binding term sheet to divest its legacy Mazindol portfolio to REA Holdings Inc. This transaction, announced on November 4, 2026, is expected to provide NewcelX with immediate cash and the potential for future earnings through milestone payments.

The deal includes an upfront payment of $500,000, which consists of $30,000 in cash and the remainder in shares, representing a 9.4% equity stake in REA Holdings. Additionally, NewcelX stands to gain up to $55 million in potential milestone payments, along with tiered royalties ranging from 2% to 8% on annual global net sales of Mazindol products.

This divestiture is a strategic decision for NewcelX, allowing the company to concentrate on its core focus of developing stem-cell-derived therapies for Type 1 Diabetes. The move is also seen as a way to preserve potential future value for the holders of contingent value rights (CVR) associated with the Mazindol assets.

Background

NewcelX Ltd. is a biopharmaceutical company focused on regenerative medicine, specifically developing therapies for Type 1 Diabetes. The company operates under the Standard Industrial Classification (SIC) code 2834, which pertains to pharmaceutical preparations. NewcelX trades on the Nasdaq under the ticker symbol NCEL.

In its recent filings, NewcelX has demonstrated a commitment to advancing its innovative therapies while managing its portfolio strategically. The divestiture of the Mazindol portfolio marks a pivotal moment in the company's evolution.

What the Filing Says

According to the filing, “NewcelX has entered into a binding term sheet for the proposed acquisition of its worldwide Mazindol asset portfolio with REA Holdings.” The agreement is intended to facilitate the future development and commercialization of the Mazindol assets while allowing NewcelX to maintain its focus on its primary therapeutic pipeline.

The filing further states that the transaction is subject to customary closing conditions and the execution of definitive documentation.

Impact

This divestiture is likely to impact various stakeholders, including NewcelX's shareholders, who may benefit from the potential milestone payments and royalties. Additionally, the move could influence the pharmaceutical industry by encouraging other companies to consider similar strategic divestitures to enhance their operational focus and financial health.

What's Next

The filing does not specify what happens next, but it indicates that the parties will proceed with the preparation and negotiation of definitive transaction documentation.